Rabies immune globulin (KedRab)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yashasvi Aryaputra[2];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Rabies immune globulin (KedRab) is a human rabies immunoglobulin (HRIG) that is FDA approved for the passive, transient post-exposure prophylaxis of rabies infection. Common adverse reactions include injection site pain, headache, muscle pain, and upper respiratory tract infection.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications:
- KEDRAB is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.
- Do not administer additional (repeat) doses of KEDRAB once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine.
- Do not administer KEDRAB to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titer.1
Dosage:
- Post-exposure prophylaxis consists of a single dose of KEDRAB and a full course of rabies vaccine. The recommended dose of KEDRAB is 20 IU/kg body weight, given at the time of the first vaccine dose. KEDRAB and the first dose of rabies vaccine should be given as soon as possible after exposure, as delays are potentially lethal. However, should a delay occur, KEDRAB should be administered at any time up to and including seven days after the first dose of vaccine. The rabies vaccine should be given according to the manufacturer's instructions.
- No more than the recommended dose of KEDRAB should be given because KEDRAB partially suppresses active antibody production following vaccination. For the same reason, additional doses of KEDRAB should not be given, even if the antibody response to vaccination is delayed.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Rabies immune globulin (KedRab) Off-Label Guideline-Supported Use and Dosage (Adult) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding Rabies immune globulin (KedRab) Off-Label Non-Guideline-Supported Use and Dosage (Adult) in the drug label.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Indications:
- KEDRAB is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.
- Do not administer additional (repeat) doses of KEDRAB once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine.
- Do not administer KEDRAB to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titer.1
Dosage:
- Post-exposure prophylaxis consists of a single dose of KEDRAB and a full course of rabies vaccine. The recommended dose of KEDRAB is 20 IU/kg body weight, given at the time of the first vaccine dose. KEDRAB and the first dose of rabies vaccine should be given as soon as possible after exposure, as delays are potentially lethal. However, should a delay occur, KEDRAB should be administered at any time up to and including seven days after the first dose of vaccine. The rabies vaccine should be given according to the manufacturer's instructions.
- No more than the recommended dose of KEDRAB should be given because KEDRAB partially suppresses active antibody production following vaccination. For the same reason, additional doses of KEDRAB should not be given, even if the antibody response to vaccination is delayed.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Rabies immune globulin (KedRab) Off-Label Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Non–Guideline-Supported Use
There is limited information regarding Rabies immune globulin (KedRab) Off-Label Non-Guideline-Supported Use and Dosage (Pediatric) in the drug label.
Contraindications
- None
Warnings
Previous Rabies Vaccination
- Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB, because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP)1.
Anaphylactic Shock
- KEDRAB should not be injected into a blood vessel because of the risk of severe allergic or hypersensitivity reactions, including anaphylactic shock. KEDRAB can induce a fall in blood pressure associated with an anaphylactic reaction, even in patients who tolerated previous treatment with human immunoglobulin.
- Discontinue KEDRAB injection immediately if there is an allergic or anaphylactic type reaction. In case of shock, implement standard medical treatment. Epinephrine should be available for treatment of acute anaphylactic symptoms.
Hypersensitivity
- Patients with a history of prior systemic allergic reactions following administration of human immune globulin preparations should be monitored for hypersensitivity.
- KEDRAB contains a small quantity of IgA. Patients who are deficient in IgA have the potential to develop IgA antibodies and may have anaphylactic reactions following administration of blood components containing IgA. The healthcare provider should assess the risks of this reaction against the benefits of administering KEDRAB.
Thrombosis
- Patients at increased risk of thrombosis or thrombotic complications should be monitored for at least 24 hours after KEDRAB administration.
- Patients at increased risk of thrombosis include patients with acquired or hereditary hypercoagulable states, prolonged immobilization, in-dwelling vascular catheters, advanced age, estrogen use, a history of venous or arterial thrombosis, cardiovascular risk factors (including history of atherosclerosis and/or impaired cardiac output), and hyperviscosity syndromes (including cryoglobulinemias, fasting chylomicronemia and/or high triglyceride levels, and monoclonal gammopathies).
- Consider measurement of baseline blood viscosity in patients at risk for hyperviscosity.
Hemolysis
- Hemolysis may occur in patients receiving immune globulin products, particularly those who are determined to be at increased risk. Patients at increased risk include those with non-O blood group types, those with underlying associated inflammatory conditions, and those receiving high cumulative doses of immune globulins over the course of several days.
- Clinical symptoms and signs of hemolysis include fever, chills and dark urine. If any of these occur, perform appropriate laboratory testing and administer medical therapy as indicated.
Live Attenuated Virus Vaccines
- KEDRAB administration may interfere with the development of an immune response to live attenuated virus vaccines.
- Avoid immunization with measles vaccine within 4 months after KEDRAB administration.
- Avoid immunization with other live attenuated virus vaccines within 3 months after KEDRAB administration.
Interference with Serologic Testing
- A transient rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results of serologic tests after KEDRAB administration.
- Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs' test).
Transmissible Infectious Agents
- KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
- The risk of transmitting an infectious agent has been minimized by
- Screening plasma donors for prior exposure to certain viruses.
- Testing for certain viral infections.
- Inactivating and removing certain viruses during the manufacturing process.
Despite these measures, KEDRAB administration can still potentially transmit infectious diseases. There is also the possibility that unknown infectious agents may be present in KEDRAB.
Any infection considered to have possibly been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. Customer Service (1-855-353-7466) or FDA at 1-800-FDA-1088.
Adverse Reactions
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates of adverse reactions in clinical trials of another drug and may not reflect the rates observed in clinical practice.
- KEDRAB was evaluated in three single-center, controlled clinical trials. Subjects in the clinical studies of KEDRAB were healthy adults, primarily white and ranged in age from 18 to 72 years. A total of 160 subjects were treated in these three studies, including 91 subjects who received single intramuscular doses of KEDRAB (20 IU/kg) with or without rabies vaccine.
- TABLE 1 summarizes adverse events (assessed by the investigator as related or unrelated to study treatment) occurring in >3% of subjects in the clinical trials of KEDRAB. The most frequent adverse events in the KEDRAB group (>6%) were injection site pain, headache, muscle pain, and upper respiratory tract infection (TABLE 1).
_Adverse_Reactions_Table.png)
- Less common adverse events were joint pain, dizziness, fatigue, abdominal pain, blood in urine, nausea, feeling faint, bruising, sunburn, and white blood cells in urine.
Postmarketing Experience
There is limited information regarding Rabies immune globulin (KedRab) Postmarketing Experience in the drug label.
Drug Interactions
- Do not administer additional (repeat) doses of KEDRAB once vaccination has been initiated, since additional doses of KEDRAB may interfere with the immune response to the vaccine.
- Do not administer KEDRAB into the same anatomical site(s) as rabies vaccine.
- KEDRAB contains other antibodies that may interfere with the response to live vaccines such as measles, mumps, polio or rubella. Avoid immunization with live virus vaccines within 3 months after KEDRAB administration, or in the case of measles vaccine, within 4 months after KEDRAB administration.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): Risk Summary
- KEDRAB has not been studied in pregnant women. Therefore, the risk of major birth defects and miscarriage in pregnant women who are exposed to KEDRAB is unknown. Animal developmental or reproduction toxicity studies have not been conducted with KEDRAB. It is not known whether KEDRAB can cause harm to the fetus when administered to a pregnant woman or whether KEDRAB can affect reproductive capacity. In the U.S. general population, the estimated background of major birth defects occurs in 2-4% of the general population and miscarriage occurs in 15-20% of clinically recognized pregnancies.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Rabies immune globulin (KedRab) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Rabies immune globulin (KedRab) during labor and delivery.
Nursing Mothers
Risk Summary
- There is no information regarding the presence of KEDRAB in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KEDRAB and any potential adverse effects on the breastfed infant from KEDRAB or from the underlying maternal condition.
Pediatric Use
- The safety and effectiveness of KEDRAB in the pediatric population have not been established.
Geriatic Use
- Clinical studies of KEDRAB did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Clinical experience with HRIG products has not identified differences in effectiveness between elderly and younger patients (ACIP)1.
Gender
There is no FDA guidance on the use of Rabies immune globulin (KedRab) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Rabies immune globulin (KedRab) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Rabies immune globulin (KedRab) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Rabies immune globulin (KedRab) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Rabies immune globulin (KedRab) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Rabies immune globulin (KedRab) in patients who are immunocompromised.
Administration and Monitoring
Administration
- When the bite site is known and infiltration at the bite site is feasible:
- Infiltrate as much of the dose as possible into and around any detectable bite wounds. Inject any remaining volume intramuscularly into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh. Administer the remaining KEDRAB at site(s) distant from the site of the rabies vaccine.
- Avoid administration into the gluteal region, where absorbance is unpredictable (unless the exposure site is in the gluteal region):
- When the bite site is unknown or indeterminate (undetectable) or if infiltration is difficult at the bite site (e.g., lips, fingers, knee), administer the full KEDRAB dose by the intramuscular route at a site distant from the site of rabies vaccination.
- If a large intramuscular volume is required (>2 mL for children or >5 mL for adults), administer the total volume in divided doses at different sites.
- If intramuscular administration is contraindicated (e.g., in patients with uncorrectable bleeding disorders), administer KEDRAB subcutaneously. However, note that there are no clinical efficacy data to support administration of KEDRAB by the subcutaneous route.
- Do not mix with the rabies vaccine or administer in the same syringe with the rabies vaccine.
- Do not administer into the same anatomical site(s) as rabies vaccine.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If either of these conditions exists, DO NOT use KEDRAB; discard the vial.
Monitoring
- Blood viscosity: At baseline in patients at risk for hyperviscosity.
- Signs and symptoms of thrombosis: In patients at risk for thrombosis or thrombotic complications, for at least 24 hours after administration.
- Signs and symptoms of hypersensitivity: In patients with a history of prior systematic allergic reactions after administration of human immune globulin products.
- Signs and symptoms of hemolysis.
IV Compatibility
There is limited information regarding the compatibility of Rabies immune globulin (KedRab) and IV administrations.
Overdosage
There is limited information regarding Rabies immune globulin (KedRab) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Rabies immune globulin (KedRab)
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | J06 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | ? |
Mechanism of Action
- Rabies is a zoonotic disease caused by RNA viruses in the family Rhabdoviridae, genus Lyssavirus. Virus is typically present in the saliva of rabid mammals and is transmitted primarily through a bite. KEDRAB is infiltrated into the inoculation site (i.e., at the beginning of anti-rabies PEP) to previously unvaccinated persons, to provide immediate passive rabies virus neutralizing antibody protection until the patient's immune system responds to vaccination by actively producing antibodies.
Structure
There is limited information regarding Rabies immune globulin (KedRab) Structure in the drug label.
Pharmacodynamics
- A protective threshold for rabies virus neutralizing activity (RVNA) has never been established. However, the WHO has generally accepted a RVNA of at least 0.5 IU/mL measured 14 days after initiation of PEP as protective. By comparison, the ACIP recommends complete neutralization of rabies virus at a 1:5 serum dilution by a rapid fluorescent focus inhibition test (RFFIT) from 1 to 2 weeks after prophylaxis; this corresponds to RVNA ~0.1-0.2 IU/mL. In support of these recommendations, there has been almost no documented clinical disease when the current rabies PEP regimen is administered appropriately (ACIP) 1.
- KEDRAB has the potential to attenuate the patient's immune response to rabies vaccine. This was evaluated in a double-blind, randomized study where 16 healthy subjects were administered either KEDRAB (20 IU/kg IM) or saline placebo followed by three doses of a rabies vaccine (TABLE 3). Lower RVNA levels were seen in the KEDRAB + vaccine group compared to the placebo + vaccine group at all time-points beginning on Day 14, confirming that KEDRAB interferes with the host immune response to rabies vaccine.
Pharmacokinetics
- A randomized, single-dose, two-period, two-treatment, two-sequence, double-blind, crossover study assessed the pharmacokinetics of KEDRAB. Twenty-six healthy volunteer subjects were randomized to receive a single IM injection of 20 IU/kg HRIG on two separate occasions (KEDRAB or Comparator HRIG). Subjects received the second treatment (A or B) following the 42-day test period and a 21-day washout period. Single dose IM injection of KEDRAB resulted in maximum plasma RVNA levels of 0.25 IU/mL. The median Tmax was 7 days (range: 3 – 14 days). The elimination half-life was approximately 17.9 days. A statistical analysis of the pharmacokinetic parameters showed that KEDRAB was not bioequivalent to the Comparator HRIG (TABLE 3).
_Pharmacokinetics_Table_1.png)
- A plot of plasma rabies virus neutralizing antibody titer concentration versus time (FIGURE 1) demonstrated that, in both treatment groups, plasma rabies virus neutralizing antibody concentrations declined in a biphasic manner after the absorption phase was complete.
_Pharmacokinetics_Figure_1.png)
- Additionally, a prospective, randomized, double-blind, non-inferiority, study evaluated the pharmacokinetics, safety and effectiveness of simulated post-exposure prophylaxis with KEDRAB with co-administration of active rabies vaccine in 118 healthy subjects. Subjects were randomized into two treatment groups (59 per treatment group) to receive intramuscular KEDRAB or comparator HRIG at a dose of 20 IU/kg on Day 0, and rabies vaccine on Days 0, 3, 7, 14 and 28. The peak plasma RVNA was 71.9 IU/mL and 53.9 IU/mL for KEDRAB and comparator HRIG respectively. For both treatment groups, the median Tmax was 14 days (range: 14 – 49 days). The half-lives were 48.6 hours and 52.7 hours for KEDRAB and comparator HRIG respectively.
- Bioequivalent assessment showed that KEDRAB was not bioequivalent to the comparator HRIG when co-administered with a five-dose rabies vaccine regimen (TABLE 4). Furthermore, the RVNA on Day 3 was lower in the KEDRAB with rabies vaccine group relative to the Comparator HRIG with vaccine group (0.188±0.051 vs 0.229±0.054, P=0.0005). However, these pharmacokinetic differences are not expected to affect clinical outcomes.
_Pharmacokinetics_Table_2.png)
Nonclinical Toxicology
Animal Toxicology and/or Pharmacology
- Intramuscular administration of a single dose of KEDRAB to rats at 60 and 120 IU/kg (3-fold and 6-fold higher than the recommended human dose of 20 IU/kg), did not result in any signs of toxicity.
Clinical Studies
- The efficacy of KEDRAB administered concurrently with rabies vaccine was studied in a single-center, randomized, comparator HRIG-controlled clinical study. Study subjects were healthy adults 18 to 72 years of age who were without significant acute or chronic illness. A total of 118 subjects (59 per treatment group) received intramuscular KEDRAB or comparator HRIG at a dose of 20 IU/kg on Day 0, and rabies vaccine on Days 0, 3, 7, 14 and 28. The mean age of study subjects was 45 years; subjects were, predominantly white (93%), and 64% were women. The efficacy variable was RVNA, as assessed by RFFIT, on Day 14. Efficacy analyses were performed on the As-Treated Population, which comprised the 116 study subjects who received KEDRAB or comparator HRIG and at least 3 of the 5 doses of rabies vaccine before Day 14.
- Efficacy, considered when RVNA titer is 0.5 IU/mL or higher on Day 14 (as established by the WHO), was met by 56/57 subjects (98.2%) in the KEDRAB group and 59/59 subjects in the comparator HRIG group (TABLE 5). The lower limit of the 90% CI was greater than the pre-specified non-inferiority margin of -10%; thus, KEDRAB was non-inferior to comparator HRIG.
_Clinical_Studies_Table.png)
- Additional efficacy analyses included pharmacokinetics.
How Supplied
- Each carton of KEDRAB contains a single-use vial containing 2 mL or 10 mL of ready-to-use solution with a potency of 150 IU/mL.
- The 2-mL vial contains a total of 300 IU which is sufficient for a child weighing 15 kg (33 lb). (NDC 76125-150-02). The 10-mL vial contains a total of 1500 IU which is sufficient for an adult weighing 75 kg (165 lb). (NDC 76125-150-10).
Storage
- Store KEDRAB at 2-8 °C (36-46 °F). Do not freeze.
- Keep vial in carton until use.
- KEDRAB may be stored at room temperatures not exceeding 25 °C (77 °F) for up to one month.
- Use within one month after removal from refrigeration, Do not return to refrigeration.
- Do not use after the expiration date printed on the label.
Images
Drug Images
{{#ask: Page Name::Rabies immune globulin (KedRab) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
_Package_Label_1.jpeg)
_Package_Label_2.jpeg)
_Package_Label_3.jpeg)
_Package_Label_4.jpeg)
{{#ask: Label Page::Rabies immune globulin (KedRab) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- The KEDRAB manufacturing process includes three valid and effective viral elimination steps. In addition, the process allows the removal of thrombogenic activity.
- Inform patients that KEDRAB is made from human plasma and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk of KEDRAB transmitting an infectious agent has been reduced by screening the plasma donors, by testing the donated plasma for certain virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing. Inform patients of symptoms of a possible viral infection, including headache, fever, nausea, vomiting, weakness, malaise, diarrhea, or, in the case of hepatitis, jaundice.
Precautions with Alcohol
Alcohol-Rabies immune globulin (KedRab) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
- KedRab
Look-Alike Drug Names
There is limited information regarding Rabies immune globulin (KedRab) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.